-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – R3R-01 in Focal Segmental Glomerulosclerosis (FSGS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - R3R-01 in Focal Segmental Glomerulosclerosis (FSGS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.R3R-01 in Focal Segmental Glomerulosclerosis (FSGS)Drug Details:R3R-01 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Atrasentan Hydrochloride in Focal Segmental Glomerulosclerosis (FSGS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atrasentan Hydrochloride in Focal Segmental Glomerulosclerosis (FSGS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Atrasentan Hydrochloride in Focal Segmental Glomerulosclerosis (FSGS) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BI-764198 in Focal Segmental Glomerulosclerosis (FSGS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BI-764198 in Focal Segmental Glomerulosclerosis (FSGS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BI-764198 in Focal Segmental Glomerulosclerosis (FSGS)Drug Details:BI-764198 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – D-410101 in Focal Segmental Glomerulosclerosis (FSGS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - D-410101 in Focal Segmental Glomerulosclerosis (FSGS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. D-410101 in Focal Segmental Glomerulosclerosis (FSGS) Drug Details: D-410101...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RG-6115 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6115 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6115 in Triple-Negative Breast Cancer (TNBC) Drug Details: RG-6115 (RO-7119929)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Propagermanium in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Propagermanium in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Propagermanium in Chronic Kidney Disease (Chronic Renal Failure)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Atrasentan Hydrochloride in IgA Nephropathy (Berger’s Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atrasentan Hydrochloride in IgA Nephropathy (Berger's Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Atrasentan Hydrochloride in IgA Nephropathy (Berger's Disease) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tegoprubart in Amyotrophic Lateral Sclerosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tegoprubart in Amyotrophic Lateral Sclerosis Drug Details: Tegoprubart is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nimacimab in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nimacimab in Obesity report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nimacimab in Obesity Drug Details: Nimacimab (RYI-018) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Baricitinib in Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Baricitinib in Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Baricitinib in Systemic-Onset Juvenile Idiopathic Arthritis (Still...